New IVF drug trial halted early: did it help embryo growth?

NCT ID NCT06466486

Terminated Disease control Sponsor: Ferring Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested whether adding the drug FE999302 to standard IVF hormones could increase the number of high-quality embryos in women undergoing fertility treatment. The study enrolled 310 women aged 18–40 with specific hormone levels. The trial was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FERTILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FERTILITY

Contacts and locations

Locations

Ferring Investigational Site

Brussels, 1090, Belgium
Ferring Investigational Site

Edegem, 2650, Belgium
Ferring Investigational Site

Prague, Prague, 150 00, Czechia
Ferring Investigational Site

Prague, 160 00, Czechia
Ferring Investigational Site

Prague, 184 00, Czechia
Ferring Investigational Site

Hvidovre, Hvidovre, 2650, Denmark
Ferring Investigational Site

Copenhagen, 2100, Denmark
Ferring Investigational Site

Trondheim, Sor-Trondelag, 7042, Norway
Ferring Investigational Site

Bergen, 5006, Norway
Ferring Investigational Site

Porsgrunn, 3913, Norway
Ferring Investigational Site

Madrid, Aravaca, 28023, Spain
Ferring Investigational Site

Barcelona, 08028, Spain
Ferring Investigational Site

Madrid, 28010, Spain
Ferring Investigational Site

Seville, 41092, Spain
Ferring Investigational Site

Valencia, 46015, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.